Desitin Pharmaceuticals GmbH

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Rznomics To Partner With Lilly On

GlaxoSmithKline has sold its US rights to migraine drug Treximet (sumatriptan/naproxen) to Pernix Therapeutics for $250m. GSK licensed the rights from Pozen under a collaboration that began in 2003. U

IN VITRO DIAGNOSTICS Mergers & Acquisitions Agilent Technologies Inc. Dako AS Expanding its presence in the diagnostics market, life sciences company Agilent Technologies Inc. will pay $2.2bn in c

Pozen, a drug developer based in Chapel Hill, North Carolina, has signed a licensing deal with the private German company Desitin Pharmaceuticals for the development and commercialisation of a migrain